Lenalidomide is an immunomodulatory agent that downregulates IRF4/MUM1 and subsequently decreases BCR-dependent NF-κB activity in ABC-DLBCL cells in vitro and in tumor xenograft models66. Here, IRF4 is linked to neoplasm.